ArticleClinical and experimental medicine2022
miR-522 regulates cell proliferation, migration, invasion capacities and acts as a potential biomarker to predict prognosis in triple-negative breast cancer.
Article in Clinical and experimental medicine, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
4 citing papers in PubMed, 11 citations in OpenAlex.
- Hippo Signaling Dysregulation in Breast Cancer: Subtype-Independent Gene and miRNA Signatures.Biomedicines · 2025Article
- Diagnosis, Prognosis, and Treatment of Triple-Negative Breast Cancer: A Review.Breast cancer (Dove Medical Press) · 2025Review
- ER Negative Breast Cancer and miRNA: There Is More to Decipher Than What the Pathologist Can See!Biomedicines · 2023Review
- Advances in Electrochemical Biosensor Technologies for the Detection of Nucleic Acid Breast Cancer Biomarkers.Sensors (Basel, Switzerland) · 2023Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
This study was designed to explore the cell functions and prognostic significance of miR-522 in triple-negative breast cancer. The expression levels of miR-522 in triple-negative breast cancer tissues and cell lines were detected by quantitative real-time PCR analysis. Kaplan-Meier curve and Cox regression analysis were used to investigate the relationship between miR-522 expression and prognosis of patients, and to evaluate the possibility of miR-522 as a potential indicator for predicting the prognosis of triple-negative breast cancer. The CCK-8 and transwell assays were used to assess cell proliferation, migration, and invasion abilities. The expression of miR-522 in triple-negative breast cancer tissues was significantly higher than that in adjacent tissues and its high expression was closely associated with the high incidence of lymph node metastasis, advanced TNM stage, and BRCA1/2 mutation status. High expression of miR-522 is correlated with poor overall survival in patients with triple-negative breast cancer. Besides, functional studies in two triple-negative breast cancer cell lines showed that overexpression of miR-522 significantly promoted cell proliferation, migration, and invasion in vitro. BRCA1 was a potential direct target of miR-522. Our findings indicated that miR-522 was highly expressed in triple-negative breast cancer and was associated with poor prognosis of patients. The upregulation of miR-522 accelerated the progression of triple-negative breast cancer by targeting BRCA1. Therefore, miR-522 provides valuable information for the development of prevention and treatment strategies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.